You are hereHome › For Physicians
OncoGenex is a leader in the development of novel therapeutics that target important mechanisms of treatment resistance in cancer. We are committed to the development and commercialization of first-in-class, innovative therapies that have the potential to redefine treatment outcomes for patients with a variety of cancers.
Custirsen is an experimental drug that is designed to block the production of the protein clusterin, which may play a fundamental role in cancer cell survival and treatment resistance. Clusterin is upregulated in tumor cells in response to treatment interventions such as chemotherapy, hormone ablation and radiation therapy and has been found to be overexpressed in a number of cancers, including prostate, lung, breast and bladder. Increased clusterin production has been linked to faster rates of cancer progression, treatment resistance and shorter survival duration. By inhibiting clusterin, custirsen is designed to alter tumor dynamics, slowing tumor growth and resistance to partner treatments, so that the benefits of therapy, including survival, may be extended.
As part of Phase 1 and Phase 2 clinical trials, custirsen was administered to 294 patients with various types of cancer. The majority of adverse events were mild. The most common adverse events associated with custirsen consisted of flu-like symptoms. The most common serious adverse events (SAE) associated with custirsen were febrile neutropenia, fever, pleural effusion, and dyspnea. Each SAE event was observed in approximately 2%-4% of patients.
Apatorsen (OGX-427) is designed to inhibit production of heat shock protein 27 (Hsp27), an intracellular protein that is elevated in many types of cancer. By inhibiting Hsp27, apatorsen may disable cancer cells’ defenses and overcome treatment resistance. Both the potential single-agent activity and synergistic activity of apatorsen with cancer treatments may increase the overall benefit of existing therapies and augment the durability of treatment outcomes, which could lead to increased patient survival.
Combination with 2nd-line chemotherapy (AFFINITY)
Non-small cell lung cancer
Combination with 2nd-line chemotherapy (ENSPIRIT)
Combination with 1st-Line Chemo (metastatic) (Borealis-1™)
Combination with 2nd-Line Chemo (metastatic) (Borealis-2™)
Non-squamous non–small cell lung cancer
Combination with 1st-line chemotherapy (advanced) (Spruce™)
Squamous non–small cell lung cancer
Combination with 1st-line chemotherapy (advanced) (Spruce-2™)
Combination with 1st-line chemotherapy (metastatic) (Rainier™)
Combination with prednisone (pre-chemo)
Combination with abiraterone acetate (pre- or post-chemo) (Pacific™)
Current as of January 2015.
Daniel Cain, Director, Clinical Research
“Our goal is to enhance treatment paradigms across tumor types with the idea of helping current and emerging therapies work better and longer rather than simply replacing existing treatments.”